MCID: DBT002
MIFTS: 45

Diabetic Autonomic Neuropathy

Categories: Neuronal diseases

Aliases & Classifications for Diabetic Autonomic Neuropathy

MalaCards integrated aliases for Diabetic Autonomic Neuropathy:

Name: Diabetic Autonomic Neuropathy 12 55 15 72
Diabetic Neuropathies 44 72

Classifications:



External Ids:

Disease Ontology 12 DOID:11503
MeSH 44 D003929
NCIt 50 C27068
SNOMED-CT 68 50620007
UMLS 72 C0011882 C0271686

Summaries for Diabetic Autonomic Neuropathy

MalaCards based summary : Diabetic Autonomic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 5, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Autonomic Neuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Quinapril and Bromocriptine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and spinal cord, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Diabetic Autonomic Neuropathy

Diseases related to Diabetic Autonomic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 33.0 NTF3 INS AKR1B1
2 microvascular complications of diabetes 5 32.4 INS AKR1B1
3 autonomic neuropathy 31.5 NGF INS AKR1B1
4 peripheral nervous system disease 30.4 NGF INS AKR1B1
5 uremia 30.0 INS EPO
6 sensory peripheral neuropathy 29.5 NTF3 NGF
7 diabetic polyneuropathy 29.4 NTF3 NGF AKR1B1
8 diabetic neuropathy 29.3 NTF3 NGF INS EPO AKR1B1
9 kidney disease 29.3 INS EPO AKR1B1
10 microvascular complications of diabetes 2 11.4
11 neuropathy 11.1
12 abducens nerve disease 11.1
13 argyll robertson pupil 11.1
14 fainting 11.1
15 syncope 11.1
16 autonomic dysfunction 10.6
17 hypoglycemia 10.5
18 pure autonomic failure 10.5
19 mononeuropathy 10.4
20 chronic pain 10.3
21 lipid metabolism disorder 10.3
22 paresthesia 10.3
23 sheehan syndrome 10.3 INS EPO
24 plethora of newborn 10.3 INS EPO
25 fetal erythroblastosis 10.3 INS EPO
26 gastroparesis 10.3
27 polyneuropathy 10.3
28 erythermalgia, primary 10.3
29 slowed nerve conduction velocity, autosomal dominant 10.3
30 hypoglycemic coma 10.3 NTF3 INS
31 cardiac conduction defect 10.3
32 resting heart rate, variation in 10.3
33 impotence 10.3
34 retinal vascular disease 10.2 INS AKR1B1
35 diabetes mellitus, insulin-dependent 10.2
36 diarrhea 10.2
37 neuroaxonal dystrophy 10.2
38 hyperglycemia 10.2
39 arthropathy 10.2
40 carpal tunnel syndrome 10.2
41 iritis 10.2
42 postherpetic neuralgia 10.2
43 functional gastric disease 10.2 MLNR INS
44 chronic inflammatory demyelinating polyneuropathy 10.1
45 amyotrophic lateral sclerosis 1 10.1
46 pain agnosia 10.1
47 lateral sclerosis 10.1
48 vasculitis 10.1
49 diabetes mellitus, noninsulin-dependent 10.1
50 sleep apnea 10.1

Graphical network of the top 20 diseases related to Diabetic Autonomic Neuropathy:



Diseases related to Diabetic Autonomic Neuropathy

Symptoms & Phenotypes for Diabetic Autonomic Neuropathy

UMLS symptoms related to Diabetic Autonomic Neuropathy:


sciatica, neuralgia

MGI Mouse Phenotypes related to Diabetic Autonomic Neuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.65 AKR1B1 INS NGF NTF3 SYNM
2 cardiovascular system MP:0005385 9.63 AOC1 EPO INS NGF NTF3 SYNM
3 muscle MP:0005369 9.35 EPO INS NGF NTF3 SYNM
4 vision/eye MP:0005391 9.02 AKR1B1 AOC1 INS NGF NTF3

Drugs & Therapeutics for Diabetic Autonomic Neuropathy

Drugs for Diabetic Autonomic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 280)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
2
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
6
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
7
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
8
Amitriptyline Approved Phase 4 50-48-6 2160
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Histamine Approved, Investigational Phase 4 51-45-6 774
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
leucovorin Approved Phase 4 58-05-9 143 6006
13
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Cetirizine Approved Phase 4 83881-51-0 2678
16
Metformin Approved Phase 4 657-24-9 4091 14219
17
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
18
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
19
Donepezil Approved Phase 4 120014-06-4 3152
20
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
23
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
24
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
25
Cobalamin Experimental Phase 4 13408-78-1 6857388
26 Antioxidants Phase 4
27 Protective Agents Phase 4
28 Lipid Regulating Agents Phase 4
29 Hypolipidemic Agents Phase 4
30 Antimetabolites Phase 4
31 Antirheumatic Agents Phase 4
32 Dopamine agonists Phase 4
33 Alpha-lipoic Acid Phase 4
34 Thioctic Acid Phase 4
35 Anesthetics, Local Phase 4
36 Amitriptyline, perphenazine drug combination Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 Anti-Inflammatory Agents Phase 4
39 Citrate Phase 4
40 Anticholesteremic Agents Phase 4
41 Anti-Allergic Agents Phase 4
42 Histamine H1 Antagonists Phase 4
43 Histamine Antagonists Phase 4
44
Histamine Phosphate Phase 4 51-74-1 65513
45 Analgesics, Non-Narcotic Phase 4
46 Vitamin B 12 Phase 4
47 Vitamin B 6 Phase 4
48 Vitamin B12 Phase 4
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4
50 Antipyretics Phase 4

Interventional clinical trials:

(show top 50) (show all 393)
# Name Status NCT ID Phase Drugs
1 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
3 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
4 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
5 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
6 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
7 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
8 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
9 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
10 A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
11 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
12 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
13 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
14 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
15 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
16 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
17 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
18 Bone Marrow Responsiveness to Pharmacologic Mobilization of Progenitor Cells in Diabetic Versus Non-diabetic Patients Completed NCT01102699 Phase 4 Filgrastim, hrG-CSF
19 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
20 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
21 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
22 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
23 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
24 A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases Completed NCT01352767 Phase 4
25 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
26 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
27 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
28 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
29 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
30 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
31 Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain. Completed NCT03047278 Phase 4 Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
32 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
33 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
34 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
35 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
36 RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
37 A Double-blind, Randomized, Parallel 2- Arm Study to Compare the Efficacy of Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes Who Are Receiving Background Standard-of-care Cardio-metabolic Therapy With Metformin, an Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker, and a Statin. Not yet recruiting NCT03640221 Phase 4 Ertugliflozin;Hydrochlorothiazide 12.5mg
38 Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Terminated NCT00619983 Phase 4 donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
39 A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Terminated NCT02156336 Phase 4 Ranolazine;Placebo
40 Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy Terminated NCT00487981 Phase 4
41 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
42 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months. Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
43 Diabetic Neuropathic Pain Topical Treatment- Comparative Study Unknown status NCT00661063 Phase 3 ketamine;vehicle gel;ketamine + clonidine;clonidine gel 1%
44 Use of Topical Lidocaine (Lidoderm 5% Patch) to Reduce Pain in Patients With Diabetic Neuropathy: Does the Density and Subtype of Sodium Channels Affect Response? Unknown status NCT01086150 Phase 2, Phase 3
45 Study of Topical Preparation of Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy Unknown status NCT01125215 Phase 2, Phase 3 0.75% capsaicin nanoparticle cream;Placebo
46 A Randomized, Sham-Controlled Clinical Study to Evaluate The Effect of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy Unknown status NCT00134524 Phase 3
47 Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KW21052 for 8 Weeks Compared to Pregabalin (Lyrica) in the Diabetic Patients With Neuropathic Pain Unknown status NCT01863810 Phase 3 KW21052;Lyrica;Lyrica (low dose);Placebo of KW21052;Placebo of Lyrica
48 The Evaluation of Safety and Efficacy of JWHGWT on Diabetic Neuropathy Unknown status NCT00886665 Phase 3 placebo;JWHGWT
49 A Randomized, Double-Blind, Placebo Controlled, Parallel Assignment, Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain Unknown status NCT01035281 Phase 3 Nabilone, flexible dosing
50 Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial Completed NCT00116207 Phase 3 ORAL ANTIOXIDANT

Search NIH Clinical Center for Diabetic Autonomic Neuropathy

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Becaplermin
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
mecobalamin
Mexiletine
Mexiletine Hydrochloride
Pentoxifylline
Vitamin B 12

Cochrane evidence based reviews: diabetic neuropathies

Genetic Tests for Diabetic Autonomic Neuropathy

Anatomical Context for Diabetic Autonomic Neuropathy

MalaCards organs/tissues related to Diabetic Autonomic Neuropathy:

41
Heart, Testes, Spinal Cord, Skin, Bone, Brain, Bone Marrow

Publications for Diabetic Autonomic Neuropathy

Articles related to Diabetic Autonomic Neuropathy:

(show top 50) (show all 1021)
# Title Authors PMID Year
1
Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. 9 38
11245210 2001
2
Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. 9 38
9647338 1998
3
Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. 9 38
18370475 1998
4
An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy. 9 38
8088110 1994
5
Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. 9 38
8299441 1993
6
Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor. 9 38
8482988 1993
7
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus. 9 38
2123430 1990
8
Commentary: Abnormal pupillary light reflexes - A sign of diabetic autonomic neuropathy. 38
31332118 2019
9
Commentary: Recognizing pupillary dysfunction in diabetic autonomic neuropathy. 38
31332119 2019
10
Association of pupil responses with severity of erectile dysfunction in diabetes mellitus. 38
31332117 2019
11
Painful and Painless Diabetic Neuropathies: What Is the Difference? 38
31065863 2019
12
Diabetic neuropathies influence recovery from hip-fracture surgery in older persons with diabetes. 38
30738920 2019
13
Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. 38
30935671 2019
14
Omega-3 polyunsaturated fatty acids exert anti-oxidant effects through the nuclear factor (erythroid-derived 2)-related factor 2 pathway in immortalized mouse Schwann cells. 38
30216708 2019
15
Uncoupling neurotrophic function from nociception of nerve growth factor: what can be learned from a rare human disease? 38
30632491 2019
16
Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy. 38
30568127 2019
17
Droxidopa for Hypotension of Different Etiologies: Two Case Reports. 38
30828233 2019
18
Early Alterations of Corneal Subbasal Plexus in Uncomplicated Type 1 Diabetes Patients. 38
31341662 2019
19
Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats. 38
30372853 2018
20
Altered pain processing in people with type I and II diabetes: a protocol for a systematic review and meta-analysis of pain threshold and pain modulation mechanisms. 38
30518431 2018
21
Involvement of P2Y12 receptor of stellate ganglion in diabetic cardiovascular autonomic neuropathy. 38
30084083 2018
22
Diabetic autonomic neuropathy resulting in sexual dysfunction. 38
30256272 2018
23
Diabetic autonomic neuropathy resulting in sexual dysfunction. 38
30320635 2018
24
Ethnic variation of IL-4 intron 3 VNTR gene polymorphism; its association with type 2 diabetes mellitus and its complication (neuropathy) in Egyptian subjects. 38
30318704 2018
25
The relationship of one-leg standing time with peripheral nerve function and clinical neuropathy in patients with type 2 diabetes. 38
30603374 2018
26
Effects of whole body vibration in individuals with diabetic peripheral neuropathy: a systematic review. 38
30179216 2018
27
Inflammatory Diabetic Neuropathy: Helpful Diagnostic Parameters. 38
30124555 2018
28
Autonomic disturbances in diabetes: Assessment and anaesthetic implications. 38
30166651 2018
29
Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice. 38
29091313 2018
30
Diffuse microvascular C5b-9 deposition is a common feature in muscle and nerve biopsies from diabetic patients. 38
29458425 2018
31
Association between a MIR499A polymorphism and diabetic neuropathy in type 2 diabetes. 38
29108839 2018
32
Prevalence of cardiovascular autonomic neuropathy and gastroparesis symptoms among patients with type 2 diabetes who attend a primary health care center. 38
30576362 2018
33
Predictors of Cardiovascular Autonomic Neuropathy Onset and Progression in a Cohort of Type 1 Diabetic Patients. 38
29693021 2018
34
[Diabetic and non-diabetic neuropathies in patients with diabetes mellitus]. 38
29863704 2018
35
Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension. 38
28623420 2017
36
Assessment of diabetic neuropathy with emission tomography and magnetic resonance spectroscopy. 38
28234786 2017
37
Advanced glycation end products induce brain-derived neurotrophic factor release from human platelets through the Src-family kinase activation. 38
28178976 2017
38
Cutaneous manifestations of diabetic peripheral neuropathy. 38
29484103 2017
39
Role of "Sural Sparing" Pattern (Absent/Abnormal Median and Ulnar with Present Sural SNAP) Compared to Absent/Abnormal Median or Ulnar with Normal Sural SNAP in Acute Inflammatory Demyelinating Polyneuropathy. 38
29085327 2017
40
Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways. 38
27341846 2017
41
The Preferential Impairment of Pupil Constriction Stimulated by Blue Light in Patients with Type 2 Diabetes without Autonomic Neuropathy. 38
28421205 2017
42
Cardiac Autonomic Neuropathy: Why Should Cardiologists Care about That? 38
29214181 2017
43
Treatment of Diabetic Autonomic Neuropathy in Older Adults with Diabetes Mellitus. 38
28107120 2016
44
Cardiac autonomic neuropathy risk estimated by sudomotor function and arterial stiffness in Chinese subjects. 38
26740338 2016
45
Recent advances in exploring the genetic susceptibility to diabetic neuropathy. 38
27596057 2016
46
In vivo corneal confocal microscopy in diabetes: Where we are and where we can get. 38
27660697 2016
47
Severe Pain and Edema due to a Widespread Lymphangioma: Disappearance of Symptoms and Reduction of Lesion with Spinal Cord Stimulation. 38
27402439 2016
48
Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. 38
27352953 2016
49
Assessment of the cardiovascular and gastrointestinal autonomic complications of diabetes. 38
27625746 2016
50
Foot bone density in diabetes may be unaffected by the presence of neuropathy. 38
27156167 2016

Variations for Diabetic Autonomic Neuropathy

Expression for Diabetic Autonomic Neuropathy

Search GEO for disease gene expression data for Diabetic Autonomic Neuropathy.

Pathways for Diabetic Autonomic Neuropathy

Pathways related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.76 NTF3 NGF INS EPO
2 11.27 NTF3 NGF
3
Show member pathways
11.14 NTF3 NGF
4
Show member pathways
11.04 NTF3 NGF
5 10.84 INS EPO
6 10.61 NTF3 NGF

GO Terms for Diabetic Autonomic Neuropathy

Cellular components related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.1 NTF3 NGF INS EPO AOC1 AKR1B1
2 adherens junction GO:0005912 8.96 SYNM PIANP

Biological processes related to Diabetic Autonomic Neuropathy according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 memory GO:0007613 9.49 NTF3 NGF
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.48 NTF3 INS
3 neuron projection morphogenesis GO:0048812 9.46 NTF3 NGF
4 modulation of chemical synaptic transmission GO:0050804 9.43 NTF3 NGF
5 acute-phase response GO:0006953 9.4 INS EPO
6 activation of protein kinase B activity GO:0032148 9.37 NTF3 INS
7 regulation of neuron differentiation GO:0045664 9.32 NTF3 NGF
8 peripheral nervous system development GO:0007422 9.26 NTF3 NGF
9 positive regulation of Ras protein signal transduction GO:0046579 9.16 NGF EPO
10 nerve development GO:0021675 8.96 NTF3 NGF
11 nerve growth factor signaling pathway GO:0038180 8.62 NTF3 NGF

Sources for Diabetic Autonomic Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....